DoseGear research brief
First-in-class dual GLP-1 and glucagon receptor agonist combining appetite suppression with thermogenesis stimulation. Phase 3 trials demonstrated superiority over semaglutide for weight loss and glycemic control.
DG Peptide Protocols
Extensively StudiedWeight LossMetabolic
Mazdutide
IBI362
Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes
Research overview
Mechanism of action
Dual agonist activation: GLP-1 stimulates insulin, suppresses glucagon, slows gastric emptying; Glucagon increases energy expenditure and thermogenesis while GLP-1 counteracts glucose-raising effects.
Compound background
Development & research timeline
Study windows describe what researchers measured, not when an individual should expect a result.
Origin & development
Engineered dual incretin and glucagon-pathway agonist.
What it is researched for
Obesity and type 2 diabetes trials through GLP-1/glucagon-receptor agonism.
Research observation window
The source reports trial durations of 20, 32, 48, and 60 weeks; these are endpoint windows, not onset predictions.
Reference data
Lyophilized vial injectable protocols
Not personalized dosing instructions
Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.
| Research context | Amount | Frequency | Route |
|---|---|---|---|
| Weight loss initiation (3mg target) | 1.5mg → 3mg | Once weekly | SubQ |
| Weight loss progression (4.5mg target) | 1.5mg → 3mg → 4.5mg | Once weekly | SubQ |
| Weight loss optimization (6mg target) | 2mg → 4mg → 6mg | Once weekly | SubQ |
| Maximum weight loss (9mg target) | 3mg → 6mg → 9mg | Once weekly | SubQ |
| T2D management (mild-moderate) | 3-4.5mg weekly | Once weekly | SubQ |
Reference cycle
48-60+ weeks for optimal results per clinical trials
Reference storage
Refrigerate reconstituted solution at 2-8°C, use within 30 days; lyophilized powder at -20°C until reconstitution
Safety context
Reported side effects
- Nausea (mild-moderate, typically improves over time)
- Diarrhea
- Vomiting
- Increased heart rate (5-17 bpm observed)
Contraindications & cautions
- Personal or family history of medullary thyroid carcinoma
- MEN2 syndrome history (class warning for GLP-1 agonists)
- Pregnancy or breastfeeding (insufficient safety data)
Scientific references
- 01
GLORY-1 Phase 3 Trial
Scientific citationGLORY-1 Phase 3 Trial. (2025). - 02
GLORY-2 Phase 3 Trial
Scientific citationGLORY-2 Phase 3 Trial. (2025). - 03
DREAMS-3 Phase 3 Trial - Head-to-Head vs Semaglutide
Scientific citationDREAMS-3 Phase 3 Trial - Head-to-Head vs Semaglutide. (2025). - 04
Phase 2 T2D Trial
Scientific citationPhase 2 T2D Trial. (2024).
This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.